ReviewMolecules (Basel, Switzerland)2012
The pharmacological properties and therapeutic use of apomorphine.
Review in Molecules (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 94 citations in OpenAlex.
- Trial
- Dopamine transporter genotype dependent effects of apomorphine on cold pain tolerance in healthy volunteers.PloS one · 2013Trial
- A versatile yeast platform for N-demethylation of therapeutic alkaloids.Journal of biological engineering · 2026Article
- A Highly Potent Apomorphine Derivative Enhancing Neurite Outgrowth via Nrf2 Activation.Antioxidants (Basel, Switzerland) · 2025Article
- Non-Targeted Metabolomics Reveal Apomorphine's Therapeutic Effects and Lysophospholipid Alterations in Steatohepatitis.Antioxidants (Basel, Switzerland) · 2024Article
- Phytochemicals in Drug Discovery-A Confluence of Tradition and Innovation.International journal of molecular sciences · 2024Review
- Genetic Targets and Applications of Iron Chelators for Neurodegeneration with Brain Iron Accumulation.ACS bio & med chem Au · 2024Review
- Pharmacology of boldine: summary of the field and update on recent advances.Frontiers in pharmacology · 2024Review
- Personality and quality-of-life improvement after apomorphine infusion in Parkinson's disease.Brain communications · 2024Article
- Feasibility and benefits of home initiation of subcutaneous apomorphine infusion for patients with Parkinson's disease: the APOKADO study.Journal of neural transmission (Vienna, Austria : 1996) · 2023Observational
- Intermittent Apomorphine Use for off Period Rescue in Parkinson's Disease: A Pragmatic Review of over Three Decades of Clinical Experience.Movement disorders clinical practice · 2023Review
- Apomorphine Reduces A53T α-Synuclein-Induced Microglial Reactivity Through Activation of NRF2 Signalling Pathway.Cellular and molecular neurobiology · 2022Article
- Poisoning by Plants.Deutsches Arzteblatt international · 2022Article
- Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia.Molecules (Basel, Switzerland) · 2022Article
- 8-, 9-, and 11-Aryloxy Dimeric Aporphines and Their Pharmacological Activities.Molecules (Basel, Switzerland) · 2021Review
- Parkinson's Disease: Personalized Pathway of Care for Device-Aided Therapies (DAT) and the Role of Continuous Objective Monitoring (COM) Using Wearable Sensors.Journal of personalized medicine · 2021Review
- Signal transduction pathways involved in dopamine DAutonomic neuroscience : basic & clinical · 2021Article
- Dopamine receptors in emesis: Molecular mechanisms and potential therapeutic function.Pharmacological research · 2020Review
- Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease.Life (Basel, Switzerland) · 2020Review
- Ropinirole eye drops induce vomiting effectively in dogs: a randomised, double-blind, placebo-controlled clinical study.The Veterinary record · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apomorphine (APO) is an aporphine derivative used in human and veterinary medicine. APO activates D₁, D(2S), D(2L), D₃, D₄, and D₅ receptors (and is thus classified as a non-selective dopamine agonist), serotonin receptors (5HT(1A), 5HT(2A), 5HT(2B), and 5HT(2C)), and α-adrenergic receptors (α(1B), α(1D), α(2A), α(2B), and α(2C)). In veterinary medicine, APO is used to induce vomiting in dogs, an important early treatment for some common orally ingested poisons (e.g., anti-freeze or insecticides). In human medicine, it has been used in a variety of treatments ranging from the treatment of addiction (i.e., to heroin, alcohol or cigarettes), for treatment of erectile dysfunction in males and hypoactive sexual desire disorder in females to the treatment of patients with Parkinson's disease (PD). Currently, APO is used in patients with advanced PD, for the treatment of persistent and disabling motor fluctuations which do not respond to levodopa or other dopamine agonists, either on its own or in combination with deep brain stimulation. Recently, a new and potentially important therapeutic role for APO in the treatment of Alzheimer's disease has been suggested; APO seems to stimulate Aβ catabolism in an animal model and cell culture, thus reducing the rate of Aβ oligomerisation and consequent neural cell death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.